Funder
National Natural Science Foundation of China
The Research Program of Shanghai Health Commission
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference39 articles.
1. Yang P, Allen MS, Aubry MC et al (2005) Clinical features of 5,628 primary lung cancer patients: experience at mayo clinic from 1997 to 2003. Chest 128:452–462. https://doi.org/10.1378/chest.128.1.452
2. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS (2011) Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 8:135–141. https://doi.org/10.1038/nrclinonc.2011.2
3. Li JX, Huang JM, Jiang ZB, Li RZ, Sun A, Lai-Han Leung E, Yan PY (2019) Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non-small cell lung cancer. Integr Cancer Ther 18:1534735419890020. https://doi.org/10.1177/1534735419890020
4. Clark CA, Gupta HB, Sareddy G et al (2016) Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 76:6964–6974. https://doi.org/10.1158/0008-5472.CAN-16-0258
5. Zhang JJ, Zhang QS, Li ZQ, Zhou JW, Du J (2019) Metformin attenuates PD-L1 expression through activating hippo signaling pathway in colorectal cancer cells. Am J Trans Res 11:6965–6976
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献